Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism

Cancer Letters

Volumn 323, Issue 1, 2012, Pages 29-40

  Torres, María P ^a,b   Rachagani, Satyanarayana ^a   Purohit, Vinee ^b   Pandey, Poomy ^b   Joshi, Suhasini ^a   Moore, Erik D ^a   Johansson, Sonny L ^b   Singh, Pankaj K ^a,b   Ganti, Apar K ^c   Batra, Surinder K ^a,b  

^a Department of Biochemistry and Molecular Biology ^*  (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer metabolism; Natural product; Pancreatic cancer; Therapy

Indexed keywords

ANNONA MURICATA EXTRACT; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; HEXOKINASE; HEXOKINASE ISOENZYME; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENICITY; CELL DEATH; CELL HYPOXIA; CELL METABOLISM; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SCREENING; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GLYCOLYSIS; IN VIVO STUDY; INTRACELLULAR SIGNALING; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR VOLUME;

ANIMALS; ANNONA; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NECROSIS; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANNONA MURICATA;

EID: 84861819416     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.031     Document Type: Article

References (57)

1. SEER Stat Fact Sheets:Pancreas. National Cancer Institute. 10-28-2011.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62:10-29.
3. Chakraborty S., Baine M.J., Sasson A.R., Batra S.K. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim. Biophys. Acta 2011, 1815:44-64.
4. Bilimoria K.Y., Bentrem D.J., Ko C.Y., Stewart A.K., Winchester D.P., Talamonti M.S. National failure to operate on early stage pancreatic cancer. Ann. Surg. 2007, 246:173-180.
5. Bilimoria K.Y., Bentrem D.J., Ko C.Y., Tomlinson J.S., Stewart A.K., Winchester D.P., Talamonti M.S. Multimodality therapy for pancreatic cancer in the US: utilization, outcomes, and the effect of hospital volume. Cancer 2007, 110:1227-1234.
6. Smith B.D., Smith G.L., Hurria A., Hortobagyi G.N., Buchholz T.A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol. 2009, 27:2758-2765.
7. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
8. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., Bennouna J., Bachet J.B., Khemissa-Akouz F., Pere-Verge D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364:1817-1825.
9. Jansen R.J., Robinson D.P., Stolzenberg-Solomon R.Z., Bamlet W.R., de Andrade M., Oberg A.L., Hammer T.J., Rabe K.G., Anderson K.E., Olson J.E., Sinha R., Petersen G.M. Fruit and vegetable consumption is inversely associated with having pancreatic cancer. Cancer Causes Control 2011, 22:1613-1625.
10. Stan S.D., Singh S.V., Brand R.E. Chemoprevention strategies for pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:347-356.
11. L. Taylor. Technical Data Report for Graviola: Annona Muricata. Sage Press, Inc. Herbal Secrets of the Rainforest second ed., 2002.
12. Kim G.S., Zeng L., Alali F., Rogers L.L., Wu F.E., Sastrodihardjo S., McLaughlin J.L. Muricoreacin and murihexocin C, mono-tetrahydrofuran acetogenins, from the leaves of Annona muricata. Phytochemistry 1998, 49:565-571.
13. Oberlies N.H., Jones J.L., Corbett T.H., Fotopoulos S.S., McLaughlin J.L. Tumor cell growth inhibition by several annonaceous acetogenins in an in vitro disk diffusion assay. Cancer Lett. 1995, 96:55-62.
14. McLaughlin J.L. Paw paw and cancer: annonaceous acetogenins from discovery to commercial products. J. Nat. Prod. 2008, 71:1311-1321.
15. Tormo J.R., Royo I., Gallardo T., Zafra-Polo M.C., Hernandez P., Cortes D., Pelaez F. In vitro antitumor structure-activity relationships of threo/trans/threo mono-tetrahydrofuranic acetogenins: correlations with their inhibition of mitochondrial complex I. Oncol. Res. 2003, 14:147-154.
16. Chang F.R., Wu Y.C. Novel cytotoxic annonaceous acetogenins from Annona muricata. J. Nat. Prod. 2001, 64:925-931.
17. Liaw C.C., Chang F.R., Lin C.Y., Chou C.J., Chiu H.F., Wu M.J., Wu Y.C. New cytotoxic monotetrahydrofuran annonaceous acetogenins from Annona muricata. J. Nat. Prod. 2002, 65:470-475.
18. Adewole S.O., Caxton-Martins E.A. Morphological changes and hypoglycemic effects of Annona Muricata Linn. (Annonaceae) leaf aqueous extract on pancreatic B-cells of streptozotocin-treated diabetic rats. African J. Biomed. Res. 2006, 9:173-180.
19. Adeyemi D.O., Komolafe O.A., Adewole S.O., Obuotor E.M., Abiodum A.A., Adenowo T.K. Histomorphological and morphometric studies of the pancreatic islet cells of diabetic rats treated with extracts of Annona Muricata. Folia Morphol. 2010, 69:92-100.
20. Magruder J.T., Elahi D., Andersen D.K. Diabetes and pancreatic cancer: chicken or egg?. Pancreas 2011, 40:339-351.
21. Dai Y., Hogan S., Schmelz E.M., Ju Y.H., Canning C., Zhou K. Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR expression. Nutr. Cancer 2011, 63:795-801.
22. Moniaux N., Varshney G.C., Chauhan S.C., Copin M.C., Jain M., Wittel U.A., Andrianifahanana M., Aubert J.P., Batra S.K. Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J. Histochem. Cytochem. 2004, 52:253-261.
23. Torres M.P., Ponnusamy M.P., Chakraborty S., Smith L.M., Das S., Arafat H.A., Batra S.K. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol. Cancer Ther. 2010, 9:1419-1431.
24. Singh A.P., Moniaux N., Chauhan S.C., Meza J.L., Batra S.K. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 2004, 64:622-630.
25. de Sousa O.V., Vieira G.D., de Jesus R.G., Yamamoto C.H., Alves M.S. Antinociceptive and anti-inflammatory activities of the ethanol extract of Annona muricata L. leaves in animal models. Int. J. Mol. Sci. 2010, 11:2067-2078.
26. Seufferlein T. Novel protein kinases in pancreatic cell growth and cancer. Int. J. Gastrointest. Cancer 2002, 31:15-21.
27. Chang Q., Chapman M.S., Miner J.N., Hedley D.W. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC. Cancer 2010, 10:515.
28. Wei W.T., Chen H., Ni Z.L., Liu H.B., Tong H.F., Fan L., Liu A., Qiu M.X., Liu D.L., Guo H.C., Wang Z.H., Lin S.Z. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation. Int. J. Oncol. 2011, 39:1381-1390.
29. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
30. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
31. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
32. Lu H., Forbes R.A., Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 2002, 277:23111-23115.
33. Fitzpatrick S.F., Tambuwala M.M., Bruning U., Schaible B., Scholz C.C., Byrne A., O'Connor A., Gallagher W.M., Lenihan C.R., Garvey J.F., Howell K., Fallon P.G., Cummins E.P., Taylor C.T. An intact canonical NF-kappaB pathway is required for inflammatory gene expression in response to hypoxia. J. Immunol. 2011, 186:1091-1096.
34. Nam S.Y., Ko Y.S., Jung J., Yoon J., Kim Y.H., Choi Y.J., Park J.W., Chang M.S., Kim W.H., Lee B.L. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-kappaB promotes gastric tumour growth and angiogenesis. Br. J. Cancer 2011, 104:166-174.
35. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 2006, 70:1469-1480.
36. Masamha C.P., Benbrook D.M. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009, 69:6565-6572.
37. Cunningham C.C. Actin structural proteins in cell motility. Cancer Met. Rev. 1992, 11:69-77.
38. Kaverina I., Straube A. Regulation of cell migration by dynamic microtubules. Semin. Cell Dev. Biol 2011, 22:968-974.
39. Bacallao R., Garfinkel A., Monke S., Zampighi G., Mandel L.J. ATP depletion: a novel method to study junctional properties in epithelial tissues. I. Rearrangement of the actin cytoskeleton. J. Cell Sci. 1994, 107(Pt 12):3301-3313.
40. Jordan M.A., Horwitz S.B., Lobert S., Correia J.J. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine. Semin. Oncol. 2008, 35:S6-S12.
41. Zhao X., Guan J.L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv. Drug Deliv. Rev. 2011, 63:610-615.
42. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: they're not just for matrix anymore!. Curr. Opin. Cell Biol. 2001, 13:534-540.
43. Bafna S., Kaur S., Momi N., Batra S.K. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br. J. Cancer 2009, 101:1155-1161.
44. Chaturvedi P., Singh A.P., Moniaux N., Senapati S., Chakraborty S., Meza J.L., Batra S.K. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol. Cancer. Res. 2007, 5:309-320.
45. Swartz M.J., Batra S.K., Varshney G.C., Hollingsworth M.A., Yeo C.J., Cameron J.L., Wilentz R.E., Hruban R.H., Argani P. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am. J. Clin. Pathol. 2002, 117:791-796.
46. El M.N., Caro-Maldonado A., Ramirez-Peinado S., Munoz-Pinedo C. Sugar-free approaches to cancer cell killing. Oncogene 2011, 30:253-264.
47. Komar G., Kauhanen S., Liukko K., Seppanen M., Kajander S., Ovaska J., Nuutila P., Minn H. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin. Cancer Res. 2009, 15:5511-5517.
48. Vasseur S., Tomasini R., Tournaire R., Iovanna J.L. Hypoxia induced tumor metabolic switch contributes to pancreatic cancer aggressiveness. Cancers 2010, 2:2138-2152.
49. Duffy J.P., Eibl G., Reber H.A., Hines O.J. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol. Cancer 2003, 2:12.
50. Yokoi K., Fidler I.J. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin. Cancer Res. 2004, 10:2299-2306.
51. Chen E.Y., Mazure N.M., Cooper J.A., Giaccia A.J. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 2001, 61:2429-2433.
52. Amaravadi R.K., Thompson C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res. 2007, 13:7271-7279.
53. Eguchi Y., Shimizu S., Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res. 1997, 57:1835-1840.
54. Leist M., Single B., Castoldi A.F., Kuhnle S., Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 1997, 185:1481-1486.
55. Festjens N., Vanden Berghe T., Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim. Biophys. Acta 2006, 1757:1371-1387.
56. Golstein P., Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem. Sci. 2007, 32:37-43.
57. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646.